Deals in Depth: April 2009
GSK and Pfizer set up an HIV joint venture--with assets worth $373mm--that combines 17 of their drugs and compounds. GSK also made news in M&As, making a significant investment in dermatology by acquiring Stiefel Laboratories for $3.6bn. In April, device firms raised $396mm, over $100mm more than their biopharma counterparts.
You may also be interested in...
Having recently signed a gene therapy collaboration with Sarepta and received a positive opinion from the CHMP for its kidney transplant therapy, Sweden's Hansa has now raised a substantial sum in a "multiple times oversubscribed" placing.
The UK government has awarded “urgent public health status” to a clinical trial program that will test one investigational product and four existing drugs in an effort to quickly find new treatments for patients hospitalized with serious COVID-19 infection.
Kymera will receive $150m upfront from Sanofi in a deal the big pharma views as an opportunity to develop a breakthrough oral drug for atopic dermatitis and other conditions.